These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 12034248)

  • 1. Campath-1H in intestinal and multivisceral transplantation: preliminary data.
    Tzakis AG; Kato T; Nishida S; Levi D; Madariaga J; De Faria W; Nery J; Neff G; Kirk AD; Ruiz P
    Transplant Proc; 2002 May; 34(3):937. PubMed ID: 12034248
    [No Abstract]   [Full Text] [Related]  

  • 2. Daclizumab and alemtuzumab as induction agents in adult intestinal and multivisceral transplantation: rejection and infection rates in 40 recipients during the early postoperative period.
    Zanfi C; Lauro A; Cescon M; Dazzi A; Ercolani G; Grazi GL; Zanello M; Vivarelli M; Del Gaudio M; Ravaioli M; Cucchetti A; Vetrone G; Tuci F; Di Gioia P; Lazzarotto T; D'Errico A; Bagni A; Faenza S; Siniscalchi A; Pironi L; Pinna AD
    Transplant Proc; 2010; 42(1):35-8. PubMed ID: 20172276
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preliminary experience with campath 1H (C1H) in intestinal and liver transplantation.
    Tzakis AG; Kato T; Nishida S; Levi DM; Madariaga JR; Nery JR; Mittal N; Regev A; Cantwell P; Gyamfi A; Weppler D; Miller J; Tryphonopoulos P; Ruiz P
    Transplantation; 2003 Apr; 75(8):1227-31. PubMed ID: 12717207
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Daclizumab and alemtuzumab as induction agents in adult intestinal and multivisceral transplantation: A comparison of two different regimens on 29 recipients during the early post-operative period.
    Lauro A; Amaduzzi A; Dazzi A; Ercolani G; Zanfi C; Golfieri L; Grazi GL; Vivarelli M; Cescon M; Varotti G; Del Gaudio M; Ravaioli M; Siniscalchi A; Faenza S; D'Errico A; Di Simone M; Pironi L; Pinna AD
    Dig Liver Dis; 2007 Mar; 39(3):253-6. PubMed ID: 17275428
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Campath-1H immunosuppressive therapy reduces incidence and intensity of acute rejection in intestinal and multivisceral transplantation.
    Garcia M; Weppler D; Mittal N; Nishida S; Kato T; Tzakis A; Ruiz P
    Transplant Proc; 2004 Mar; 36(2):323-4. PubMed ID: 15050146
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction therapy for adult small bowel transplant with Campath-1H.
    Nishida S; Levi D; Kato T; Madariaga J; Nery J; Tzakis A
    Transplant Proc; 2002 Aug; 34(5):1889-91. PubMed ID: 12176616
    [No Abstract]   [Full Text] [Related]  

  • 7. Intestinal transplantation with alemtuzumab (Campath-1H) induction for adult patients.
    Nishida S; Levi DM; Moon JI; Madariaga JR; Kato T; Selvaggi G; Tryphonopoulos P; DeFaria W; Santiago S; Gaynor J; Weppler D; Martinez E; Ruiz P; Tzakis AG
    Transplant Proc; 2006; 38(6):1747-9. PubMed ID: 16908270
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of Campath 1H induction in adult liver allotransplantation.
    Tryphonopoulos P; Madariaga JR; Kato T; Nishida S; Levi DM; Moon J; Selvaggi G; De Faria W; Regev A; Bejarano P; Khaled A; Safdar K; Esquenazi V; Weppler D; Yoshida H; Ruiz P; Miller J; Tzakis AG
    Transplant Proc; 2005 Mar; 37(2):1203-4. PubMed ID: 15848669
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intestinal transplantation: advances in immunosuppression and surgical techniques.
    Tzakis AG; Tryphonopoulos P; Kato T; Nishida S; Levi DM; Nery JR; Madariaga J; De Faria W; Mittal N; Thompson JF; Ruiz P
    Transplant Proc; 2003 Aug; 35(5):1925-6. PubMed ID: 12962850
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Results of intestinal and multivisceral transplantation in adult patients: Italian experience.
    Lauro A; Dazzi A; Ercolani G; Cescon M; D'Errico A; Di Simone M; Grazi GL; Vivarelli M; Varotti G; De Ruvo N; Masetti M; Cautero N; Di Benedetto F; Siniscalchi A; Begliomini B; Lazzarotto T; Faenza S; Pironi L; Pinna AD
    Transplant Proc; 2006; 38(6):1696-8. PubMed ID: 16908252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alemtuzumab (Campath-1H) combined with tacrolimus in intestinal and multivisceral transplantation.
    Tzakis AG; Kato T; Nishida S; Levi DM; Tryphonopoulos P; Madariaga JR; De Faria W; Nery JR; Regev A; Vianna R; Miller J; Esquenazi V; Weppler D; Ruiz P
    Transplantation; 2003 May; 75(9):1512-7. PubMed ID: 12792506
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Preliminary experience with Campath 1H induction combined with low-dose monotherapy of tacrolimus in small bowel transplantation].
    Li YX; Li N; Ni XD; Li YS; Li M; Shen J; Li JS
    Zhonghua Wai Ke Za Zhi; 2009 Jun; 47(11):810-3. PubMed ID: 19961008
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evolution of the immunosuppressive strategies for the intestinal and multivisceral recipients with special reference to allograft immunity and achievement of partial tolerance.
    Abu-Elmagd KM; Costa G; Bond GJ; Wu T; Murase N; Zeevi A; Simmons R; Soltys K; Sindhi R; Stein W; Demetris A; Mazariegos G
    Transpl Int; 2009 Jan; 22(1):96-109. PubMed ID: 18954362
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The long-term efficacy of multivisceral transplantation.
    Madariaga JR; Reyes J; Mazariegos G; Fung JJ; Starzl TE; Abu-Elmagd K
    Transplant Proc; 2000 Sep; 32(6):1219-20. PubMed ID: 10995918
    [No Abstract]   [Full Text] [Related]  

  • 15. Recipient memory-like lymphocytes remain unresponsive to graft antigens after CAMPATH-1H induction with reduced maintenance immunosuppression.
    Trzonkowski P; Zilvetti M; Friend P; Wood KJ
    Transplantation; 2006 Nov; 82(10):1342-51. PubMed ID: 17130784
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prope tolerance with alemtuzumab.
    Calne RY
    Liver Transpl; 2005 Mar; 11(3):361-3. PubMed ID: 15719401
    [No Abstract]   [Full Text] [Related]  

  • 17. Therapeutic use of an extemporaneously prepared oral suspension of tacrolimus in pediatric patients.
    McGhee B; McCombs JR; Boyle G; Webber SA; Reyes JR
    Transplantation; 1997 Sep; 64(6):941-2. PubMed ID: 9326429
    [No Abstract]   [Full Text] [Related]  

  • 18. Subcutaneous administration of alemtuzumab in simultaneous pancreas-kidney transplantation.
    Clatworthy MR; Sivaprakasam R; Butler AJ; Watson CJ
    Transplantation; 2007 Dec; 84(12):1563-7. PubMed ID: 18165765
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Living-related donor renal transplantation in HIV+ recipients using alemtuzumab preconditioning and steroid-free tacrolimus monotherapy: a single center preliminary experience.
    Tan HP; Kaczorowski DJ; Basu A; Khan A; McCauley J; Marcos A; Fung JJ; Starzl TE; Shapiro R
    Transplantation; 2004 Dec; 78(11):1683-8. PubMed ID: 15591960
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alemtuzumab (Campath 1H) induction with tacrolimus monotherapy is safe for high immunological risk renal transplantation.
    Thomas PG; Woodside KJ; Lappin JA; Vaidya S; Rajaraman S; Gugliuzza KK
    Transplantation; 2007 Jun; 83(11):1509-12. PubMed ID: 17565326
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.